title: The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses.
abstract: The capacity of an adjuvant to reduce the amount of antigen required in vaccines would be beneficial in a variety of settings, including situations where antigen is difficult or expensive to manufacture, or in situations where demand exceeds production capacity, such as pandemic influenza. The ability to reduce antigen dose would also be a significant advantage in combination vaccines, and vaccines that by necessity must contain multiple antigens to accommodate variability between strains or genotypes. ISCOMATRIX adjuvant was compared to aluminium hydroxide adjuvant (Al(OH3)) for induction of antibody responses and dose sparing of a recombinant HIV gp120 vaccine. Neutralising antibody responses were significantly greater, at the same protein dose, when the gp120 protein was formulated with ISCOMATRIX adjuvant compared to Al(OH3). Moreover, strong responses were achieved with up to 100-fold lower doses of gp120 using ISCOMATRIX adjuvant. Therefore, ISCOMATRIX adjuvant has the potential to substantially reduce the dose of antigen required in human vaccines, without compromising the immune response.
authors.affiliation: CSL Limited, 45 Poplar Road, Parkville, Victoria 3052, Australia. Jeff.Boyle@csl.com.au
authors.forename: Jeff
authors.initials: J
authors.lastname: Boyle
authors.forename: Donna
authors.initials: D
authors.lastname: Eastman
authors.forename: Christine
authors.initials: C
authors.lastname: Millar
authors.forename: Sarina
authors.initials: S
authors.lastname: Camuglia
authors.forename: John
authors.initials: J
authors.lastname: Cox
authors.forename: Martin
authors.initials: M
authors.lastname: Pearse
authors.forename: Jeremy
authors.initials: J
authors.lastname: Good
authors.forename: Debbie
authors.initials: D
authors.lastname: Drane
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology; D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D016466:CHO Cells; D002784:Cholesterol / Q000008:administration & dosage*; D006224:Cricetinae; D003412:Cricetulus; D004306:Dose-Response Relationship, Immunologic; D004338:Drug Combinations; D006168:Guinea Pigs; D015483:HIV Antibodies / Q000097:blood*; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D010743:Phospholipids / Q000008:administration & dosage*; D012503:Saponins / Q000008:administration & dosage*; D014614:Vaccines, Synthetic / Q000008:administration & dosage*
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D004338:Drug Combinations; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C493786:ISCOMATRIX; D010743:Phospholipids; D012503:Saponins; D014614:Vaccines, Synthetic; D002784:Cholesterol